Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

651 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients.
Huber V, Di Guardo L, Lalli L, Giardiello D, Cova A, Squarcina P, Frati P, Di Giacomo AM, Pilla L, Tazzari M, Camisaschi C, Arienti F, Castelli C, Rodolfo M, Beretta V, Di Nicola M, Maio M, Del Vecchio M, de Braud F, Mariani L, Rivoltini L. Huber V, et al. Among authors: di guardo l, di nicola m, di giacomo am. J Immunother Cancer. 2021 Feb;9(2):e001167. doi: 10.1136/jitc-2020-001167. J Immunother Cancer. 2021. PMID: 33589521 Free PMC article.
Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors.
Mortarini R, Anichini A, Di Nicola M, Siena S, Bregni M, Belli F, Molla A, Gianni AM, Parmiani G. Mortarini R, et al. Among authors: di nicola m. Cancer Res. 1997 Dec 15;57(24):5534-41. Cancer Res. 1997. PMID: 9407964
Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial.
Di Nicola M, Carlo-Stella C, Anichini A, Mortarini R, Guidetti A, Tragni G, Gallino F, Del Vecchio M, Ravagnani F, Morelli D, Chaplin P, Arndtz N, Sutter G, Drexler I, Parmiani G, Cascinelli N, Gianni AM. Di Nicola M, et al. Hum Gene Ther. 2003 Sep 20;14(14):1347-60. doi: 10.1089/104303403322319426. Hum Gene Ther. 2003. PMID: 14503969 Clinical Trial. No abstract available.
Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.
Di Nicola M, Carlo-Stella C, Mortarini R, Baldassari P, Guidetti A, Gallino GF, Del Vecchio M, Ravagnani F, Magni M, Chaplin P, Cascinelli N, Parmiani G, Gianni AM, Anichini A. Di Nicola M, et al. Clin Cancer Res. 2004 Aug 15;10(16):5381-90. doi: 10.1158/1078-0432.CCR-04-0602. Clin Cancer Res. 2004. PMID: 15328176 Clinical Trial.
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.
Guidetti A, Carlo-Stella C, Ruella M, Miceli R, Devizzi L, Locatelli SL, Giacomini A, Testi A, Buttiglieri S, Risso A, Mariani L, Di Nicola M, Passera R, Tarella C, Gianni AM. Guidetti A, et al. Among authors: di nicola m. Cancer. 2011 Nov 15;117(22):5074-84. doi: 10.1002/cncr.26182. Epub 2011 May 12. Cancer. 2011. PMID: 21567384 Free article. Clinical Trial.
Predictors of CD34+ cell mobilization and collection in adult men with germ cell tumors: implications for the salvage treatment strategy.
Necchi A, Miceli R, Pedrazzoli P, Giannatempo P, Secondino S, Di Nicola M, Farè E, Raggi D, Magni M, Matteucci P, Longoni P, Milanesi M, Paternò E, Ravagnani F, Arienti F, Nicolai N, Salvioni R, Carlo-Stella C, Gianni AM. Necchi A, et al. Among authors: di nicola m. Clin Genitourin Cancer. 2014 Jun;12(3):196-202.e1. doi: 10.1016/j.clgc.2013.11.021. Epub 2013 Nov 13. Clin Genitourin Cancer. 2014. PMID: 24361054
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation.
Raggi D, Mariani L, Giannatempo P, Lo Vullo S, Giardiello D, Nicolai N, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, Calareso G, Magni M, Di Nicola M, Verzoni E, Grassi P, Procopio G, De Braud F, Pizzocaro G, Salvioni R, Necchi A. Raggi D, et al. Among authors: di nicola m. Urol Oncol. 2015 Jul;33(7):332.e19-24. doi: 10.1016/j.urolonc.2015.04.008. Epub 2015 May 16. Urol Oncol. 2015. PMID: 25985712
651 results